放射性肺炎的治疗进展

刘, 冬; 赵, 友飞; 王, 东海; 任, 孟先; 江, 后洲

doi:10.26549/yzlcyxzz.v3i6.5276

Cited by 10 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis based on previous literature suggests that [33] the risk of RP after sequential radiotherapy is higher than that of concurrent chemoradiotherapy. In addition, a study by Liu Ruifeng and others also confirmed that the incidence of grade 4 and above RP was less in the concurrent chemoradiotherapy group than in the sequential radiotherapy and chemotherapy group [34]. In further studies, the location of pneumonia in sequential chemotherapy and radiotherapy coincided with the radiation field, which may be caused by a radiotherapy recall reaction [35].…”

Section: The Modality Of Chemotherapy Combined With Radiotherapymentioning

confidence: 79%

Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy

et al. 2023

View full text Add to dashboard Cite

As one of the common complications of radiotherapy, radiation pneumonia (RP) limits the prognosis of patients. Therefore, better identifying the high-risk factors that lead to RP is essential to effectively prevent its occurrence. However, as lung cancer treatment modalities are being replaced and the era of immunotherapy has arrived, literature that reviews the parameters and mode of radiotherapy, chemotherapy drugs, targeted drugs and current hot immune checkpoint inhibitors related to RP is lacking. This paper summarizes the risk factors for radiation pneumonia by retrieving and analysing previously published literature and the results of large clinical trials. The literature primarily included retrospective analyses, including clinical trials in different periods and a part of the literature review. A systematic literature search of Embase, PubMed, Web of Science, and Clinicaltrials.gov was performed for relevant publications up to 6 Dec. 2022. Search keywords include, but are not limited to, “radiation pneumonia”, “pneumonia”, “risk factors”, “immunotherapy”, etc. The factors related to RP in this paper include physical parameters of radiotherapy, including V5, V20, and MLD; chemoradiotherapy mode and chemotherapy drugs, including paclitaxel and gemcitabine; EGFR-TKI; ALK inhibitors; antiangiogenic drugs; immune drugs and the underlying disease of the patient. We also introduce the possible mechanism of RP. In the future, we hope that this article not only sounds the alarm for clinicians but also helps to identify a method that can effectively intervene and reduce the occurrence of RP, significantly improve the quality of life and prognosis of patients, and more effectively improve the therapeutic effect of radiation therapy.

show abstract

Section: The Modality Of Chemotherapy Combined With Radiotherapymentioning

confidence: 79%